Status:
COMPLETED
Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborating Sponsors:
Janssen, LP
Conditions:
Anxiety Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic trea...
Detailed Description
Many patients with Generalized Anxiety Disorder (GAD) do not benefit or show only partial benefit from current psychotropic therapies. This trial was conducted for the purpose of determining the effec...
Eligibility Criteria
Inclusion
- Healthy on the basis of physical exam
- Treatment with one or more allowed antidepressants and/or anxiety medications for at least the past 8 weeks
- Judgement of the clinician that the patient has shown a sub-optimal response to this treatment
- Current diagnosis of Generalized Anxiety Disorder
- Maintained on a stable, therapeutic dose(s) of the allowed medication(s) for at least the past four weeks
Exclusion
- Presence of other serious medical illnesses
- Active use of cocaine or heroin
- History of suicide attempt in past 12 months
- Changes to antidepressant/anti-anxiety regimen (medication or dose) within the four weeks preceding study baseline (Day 1)
- History of clozapine use
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
301 Patients enrolled
Trial Details
Trial ID
NCT00086112
End Date
June 1 2005
Last Update
July 23 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.